Table 2.
Current immunotherapy trials for patients with relapsed/refractory AML.
| Title | Registration Number | Eligible Ages | Sponsor |
|---|---|---|---|
| Evaluating QTc, PK, safety of gemtuzumab ozogamicin (GO) in patents with CD33+ R/R AML | NCT037227750 | 12 years | Pfizer, New York, NY, USA |
| Study of Adoptive Cellular Therapy Using Autologous T Cells Transduce with Lentivirus To Express A CD33 Specific Chimeric Antigen Receptor in Patients with Relapsed or Refractory CD33-positive Acute Myeloid Leukemia | NCT03126864 | 1–80 years | MD Anderson Cancer Center, Houston, TX, USA |
| Study of Anti-CD33 Chimeric Antigen Receptor-Expressing T Cells (CD33CART) in Children and Young Adults with Relapsed/Refractory Acute Myeloid Leukemia | NCT03971799 | 1–30 years | CIBMTR: National Cancer Institute, Bethesda, MD and Children’s Hospital of Philadelphia, PA, USA |
| Study Evaluating the Safety, Tolerability, and Efficacy of FLT3 CAR-T AMG 553 in FLT3-Positive Relapsed/Refractory AML | NCT03904069 | ≥12 years | Amgen, Thousand Oaks, CA, USA |
| Genetically Modified T-cell Immunotherapy in Treating Patients with Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Plastic Plasmacytoid Dendritic Cell Neoplasm | NCT02159495 | ≥12 years | City of Hope Medical Center, Duarte, CA, USA |
| CD123/CLL1 CAR-T Cells for R/R AML | NCT03631576 | ≤70 years | Fujian Medical University, Fuzhou, China |
| CAR-T cells Therapy in Relapsed/Refractory Acute Myeloid Leukemia (AML) | NCT03473457 | ≥6 months | Zhujiang Hospital, Guangzhou, China |
| Multiple CAR-T Cell Therapy Targeting AML | NCT04010877 | ≥6 months | Shenzhen Geno-Immune Medical Institute, Shenzhen, China |
| Safety and efficacy evaluation of IM23 CAR-T cells (IM23CAR-T) | NCT03585517 | 3–80 years | Beijing Immunochina Medical Science & Technology Co., Ltd., Beijing, China |
| Study Evaluating Safety and Efficacy of CAR-T cells targeting CD123 in Patients with Acute Myelocytic Leukemia | NCT03796390 | 2–65 years | Hebei Senang Biotechnology Inc., Ltd., Shijiazhuang, China |
| CART-123 for Relapsed/Refractory Acute Myelocytic Leukemia | NCT03556982 | 14–75 years | The Affiliated Hospital fo the Chinese Academy of Military Medical Sciences, Beijing, China |
| CAR-T Cells Therapy in Relapsed/Refractory Acute Myeloid Leukemia | NCT03473457 | ≥6 months | Guangzhou, China |